**Summary of Uniphar PLCs 2025 Preliminary Results:**
Uniphar PLC, an international healthcare services company, reported strong financial results for 2025, highlighting significant growth across key metrics. The company achieved
**Organic Gross Profit Growth** 8.9%, the fastest rate since its IPO, driven by strong performance in all divisions, particularly Pharma (15.5%) and Medtech (10.5%).
**Adjusted EPS Growth** 21%, reaching 24.8 cents, supported by lower finance costs and a €35 million share buyback program.
**Revenue Growth** 11.0% to €3.1 billion, with constant currency growth at 11.1%.
**EBITDA Growth** 6.0% to €130.9 million, with organic growth at 9.0%.
**Net Bank Debt** Increased to €171.1 million, with leverage at 1.6x.
**Dividend** Total dividend of €5.2 million, representing a 5.2% per share increase year-on-year.
**Strategic Highlights**
Completed a €35 million share buyback program, repurchasing 13.4 million shares.
Acquired TouchStore to enhance digital and technology offerings in the pharmacy sector.
Progressed key strategic investments, including a new high-tech distribution facility in Ireland, scheduled for phased operation in mid-2026.
Maintained strong ESG ratings, including MSCI AAA and CDP B for the fourth consecutive year.
**Outlook**
Uniphar expects continued strong organic Gross Profit growth in line with its medium-term guidance. The company remains on track to achieve its target of €200 million EBITDA by 2028, with at least 80% of growth expected to be organic.
**CEO Comment**
Ger Rabbette, CEO, expressed satisfaction with the results, highlighting the fastest organic Gross Profit growth since IPO and strong Adjusted EPS growth. He reaffirmed confidence in achieving the 2028 EBITDA target.
**Financial Summary**
**Gross Profit** Increased 7.0% to €457.7 million, with a margin of 14.9%.
**Operating Profit** Decreased 6.2% to €76.9 million due to exceptional items.
**Profit Before Tax (Excluding Exceptionals):** Grew 17.4% to €71.8 million.
**Free Cash Flow Conversion** 99.1%, supported by favorable working capital movements.
**Divisional Performance**
**Uniphar Pharma** 15.5% organic Gross Profit growth, driven by Global Sourcing and clinical trial supply.
**Uniphar Medtech** 10.5% organic Gross Profit growth, supported by geographic expansion and new supplier rollouts.
**Uniphar Supply Chain & Retail** 4.2% organic Gross Profit growth, with strong volume growth in Supply Chain.
**Balance Sheet and Liquidity**
Robust balance sheet with net bank debt of €171.1 million and leverage at 1.6x.
Extended revolving credit facility maturity to August 2029 and placed a new €150 million term loan.
**Sustainability**
Reduced Scope 1 and 2 emissions by 29.9% since 2019.
Continued progress on Science-Based Targets and strong ESG ratings.
**Analyst Presentation**
A conference call for analysts and investors was scheduled for February 24, 2026, with details available on the company’s website.
**Conclusion**
Uniphar PLC delivered a strong performance in 2025, with significant growth across key financial metrics and strategic advancements. The company remains well-positioned for future growth, supported by its diversified healthcare services portfolio and strategic investments.